Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 17

Analysis of adverse events by frequency.

Item	Treatment group			Control group
	No. of patients with event	No. of events	Event rate (%)	No. of patients with event	No. of events	Event rate (%)
Abnormal liver function tests	8	8	4.55	8	10	4.47
Mild	5	5	2.84	6	8	3.35
Moderate	3	3	1.70	2	2	1.12
Abnormal hematology	4	6	2.27	2	3	1.12
Mild	3	5	1.70	0	0	0.00
Moderate	1	1	0.57	3	5	1.67
General Clinical Symptoms and Discomforts	0	0	0.00	1	3	0.56
Mild	2	2	1.14	1	3	0.56
Urinary tract infection	1	1	0.57	0	0	0.00
Moderate	1	1	0.57	0	0	0.00
Electrolyte disturbances	9	11	5.11	2	2	1.12
Mild	8	8	4.55	2	2	1.12
Moderate	1	3	0.57	0	0	0.00
Tumor	1	1	0.57	0	0	0.00
Benign	2	2	1.14	0	0	0.00
Malignant	0	0	0.00	0	0	0.00